{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:20:29Z","timestamp":1787818829991,"version":"build-2784847793"},"reference-count":30,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Food allergy is a growing global health concern associated with significant dietary restrictions, impaired quality of life, and risk of severe allergic reactions. Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4R\u03b1), inhibits IL-4 and IL-13 signaling and has demonstrated efficacy across multiple type 2 inflammatory diseases. This systematic review aimed to evaluate the effects of dupilumab on food allergy outcomes in pediatric and adult patients. Across studies, dupilumab treatment was consistently associated with reductions in total immunoglobulin E (IgE) and food-specific IgE levels, indicating modulation of allergic sensitization and type 2 inflammation. However, these immunologic improvements were not consistently accompanied by clinically meaningful desensitization or acquisition of food tolerance. In a phase II trial of peanut allergy, dupilumab monotherapy reduced immunologic markers but did not improve oral food challenge outcomes. When combined with oral immunotherapy, dupilumab modestly enhanced desensitization rates but did not substantially reduce treatment-related allergic reactions. Current evidence suggests that dupilumab favorably affects immunologic markers associated with food allergy, particularly total and allergen-specific IgE levels. Nevertheless, there is insufficient evidence to conclude that dupilumab alone induces sustained clinical tolerance to food allergens. Larger randomized controlled trials incorporating standardized oral food challenges and long-term follow-up are required to clarify the clinical role of dupilumab in food allergy management.<\/jats:p>","DOI":"10.3390\/ijms27177670","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:02:27Z","timestamp":1787817747000},"page":"7670","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Dupilumab on Allergen-Specific IgE Levels and Clinical Tolerance in Patients with Food Allergy: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-8118","authenticated-orcid":false,"given":"Magdalena","family":"Grze\u015bk-Kaczy\u0144ska","sequence":"first","affiliation":[{"name":"Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Kaczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Gynecological Oncology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadetta","family":"Kosztulska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rydzy\u0144ska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-0529","authenticated-orcid":false,"given":"Tomasz","family":"Rosada","sequence":"additional","affiliation":[{"name":"Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ukleja-Soko\u0142owska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/pai.13501","article-title":"Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics","volume":"32","author":"Ramsey","year":"2021","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_4","first-page":"00188","article-title":"Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics","volume":"16","author":"Wechsler","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.allmed.2024.100015","article-title":"Efficacy of dupilumab in the treatment of COPD with type 2 inflammation: A real-world study","volume":"2","author":"Shi","year":"2024","journal-title":"Allergy Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11882-023-01120-y","article-title":"Epidemiology and the Growing Epidemic of Food Allergy in Children and Adults Across the Globe","volume":"24","author":"Warren","year":"2024","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jaip.2021.02.039","article-title":"The Psychosocial Burden of Food Allergy Among Adults: A US Population-Based Study","volume":"9","author":"Warren","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e12268","DOI":"10.1002\/clt2.12268","article-title":"Efficacy and safety of oral immunotherapy for peanut, cow\u2019s milk, and hen\u2019s egg allergy: A systematic review of randomized controlled trials","volume":"13","author":"Lodge","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of Dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.anai.2025.07.023","article-title":"Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis","volume":"135","author":"Emerson","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sernicola, A., Amore, E., Rizzuto, G., Rallo, A., Greco, M.E., Battilotti, C., Svara, F., Azzella, G., Nistic\u00f2, S.P., and Dattola, A. (2024). Dupilumab as Therapeutic Option in Polysensitized Atopic Dermatitis Patients Suffering from Food Allergy. Nutrients, 16.","DOI":"10.3390\/nu16162797"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/all.16404","article-title":"Of Dupilumab in Children with Peanut Allergy: A Multicenter, Open-Label, Phase II Study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients with Peanut Allergy","volume":"80","author":"Chinthrajah","year":"2025","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12381","DOI":"10.1002\/clt2.12381","article-title":"Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients","volume":"14","author":"Hilbrands","year":"2024","journal-title":"Clin. Transl. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/1744666X.2016.1124761","article-title":"Interpreting IgE sensitization tests in food allergy","volume":"12","author":"Chokshi","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez, T., Rodriguez-Pozo, J.A., Diaz-Calvillo, P., Salazar-Nievas, M., Tercedor-Sanchez, J., Molina-Leyva, A., and Arias-Santiago, S. (2022). Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123341"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/all.14304","article-title":"Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?","volume":"75","author":"Brough","year":"2020","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3345\/cep.2023.00045","article-title":"Skin and oral intervention for food allergy prevention based on dual allergen exposure hypothesis","volume":"67","author":"Ohya","year":"2024","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.mucimm.2024.06.005","article-title":"Atopic dermatitis and food allergy: More than sensitization","volume":"17","author":"Davis","year":"2024","journal-title":"Mucosal Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the Treatment of Multiple Food Allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"AB444","DOI":"10.1016\/j.jaci.2024.12.1022","article-title":"Treatment of multi-food allergy with omalizumab compared to omalizumab-facilitated multi-allergen OIT","volume":"155","author":"Wood","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"B\u00e9gin, P., Ebisawa, M., Muraro, A., Lack, G., Greenhawt, M., Rachid, R., Vickery, B.P., Anagnostou, A., Leflein, J., and Perrett, K.P. (2026). Efficacy and Safety of Ligelizumab in Individuals with Confirmed Peanut Allergy. Allergy, Early view.","DOI":"10.1111\/all.70206"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.waojou.2022.100690","article-title":"The rationale for development of ligelizumab in food allergy","volume":"15","author":"Wood","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e131347","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"ref_29","unstructured":"U.S. National Library of Medicine (2026, April 25). Efficacy of Tezepelumab in Peanut Oral Immunotherapy ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07015996."},{"key":"ref_30","unstructured":"U.S. National Library of Medicine (2026, April 25). Long-term Extension Study of Ligelizumab in Food Allergy ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05678959."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7670\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:05:27Z","timestamp":1787817927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":30,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177670"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177670","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}